Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Unstable Angina Workup

  • Author: Walter Tan, MD, MS; Chief Editor: Eric H Yang, MD  more...
 
Updated: Nov 22, 2015
 

Approach Considerations

Simply put, the 2 fundamental questions in the approach to the patient with possible angina are the following:

  • Is this coronary artery disease (CAD)? (That is, what is the diagnosis, or what does the patient have?)
  • How dangerous is this? (That is, what is the prognosis, or what is the risk of something bad happening next?)

Therefore, a brief history and physical examination, resting 12-lead electrocardiography (ECG), and a blood draw for evaluation of cardiac enzymes should be accomplished expeditiously.

The following laboratory studies are recommended within the first 24 hours in the evaluation of a patient with unstable angina:

  • Serial cardiac biomarker assays
  • Hemoglobin level
  • Serum chemistry panel
  • Lipid panel

Numerous cardiac biomarker assays are currently available for the diagnosis of myocardial cell necrosis. Some of these, especially the troponin assays, are powerful prognostic tools as well and serve as important guides to the aggressiveness of approach.

Urinary proton nuclear magnetic resonance (1H NMR) spectroscopy–based metabolomic profiling appears to have the potential for identifying diagnostic biomarkers in the investigation of unstable angin pectoris metabolic signatures.[22]

Investigators have demonstrated enhanced expression of toll-like receptors 2 and 4 (TLR-2 and TLR-4)  on platelets in patients with acute coronary syndrome, which has potential clinical implications for prophylactic and therapeutic targets.[23]

Perform chest radiography to evaluate patients for signs of congestive heart failure (CHF) and for other causes of chest symptoms, such as pneumothorax, pulmonary infection or masses, pulmonary hypertension, and mediastinal widening.

Missed diagnosis

Patients in whom the diagnosis of myocardial infarction (MI) or unstable angina has been missed and those who are sent home from the emergency department (ED) have, respectively, a 2-fold and a 1.7-fold increased risk of death, compared with those who were admitted to the hospital.[21] This a public health issue. Indeed, up to 20% of the millions of dollars awarded in malpractice suits against ED practitioners is for missed acute coronary syndrome (ACS).[21]

A related study reported that nearly one third (32%) of patients with ACS have normal levels (< 14 ng/L) of high-sensitivity cardiac troponin (hs-cTnT) when they present to the ED with acute chest pain.[24] The majority of these patients had unstable angina. In addition, although the death rates of patients with normal hs-cTnT levels were significantly lower 1 year later than those of patients with elevated hs-cTnT levels, their acute MI rates were significantly higher.

Although eliminating missed diagnoses of acute ischemic syndromes is impossible without undue hospitalization rates and costs, this problem could be minimized by the following means:

  • Addressing factors or preconceptions that obscure the correct diagnosis in women and nonwhite patients, subgroups that are at higher risk for a missed diagnosis
  • Recognition of angina equivalents, particularly in elderly patients
  • More careful history taking to account for recent changes in the character or course of anginal symptoms
  • Use of confirmatory point-of-care cardiac enzyme assays that have a high negative predictive value in patients with nonspecific or normal ECG findings
  • Predischarge stress testing in stable patients at low risk who have a moderate likelihood of CAD
  • Awareness that absence of ECG findings or early cardiac enzyme elevation does not automatically preclude the possibility of acute ischemia, because these are merely snapshots of particular points in the course of a dynamic process
Next

Basic Blood Studies

The complete blood count (CBC) helps in ruling out anemia as a secondary cause of ACS. Leukocytosis has prognostic value in the setting of acute MI.

Close monitoring of potassium and magnesium levels is important in patients with ACS because low levels may predispose them to ventricular arrhythmias. Routine measurement of serum potassium levels and prompt correction are recommended.

A creatinine level is also needed, particularly if cardiac catheterization is considered. Use of N -acetylcysteine and adequate hydration can help prevent contrast material–induced nephropathy.[25]

Previous
Next

Cardiac Biomarkers

Creatine kinase, CK-MB, and troponin

Absolute elevations of creatine kinase and its MB isoenzyme (CK-MB) or troponin levels are highly specific evidence of myocardial cell death and distinguish non−ST-elevation MI (NSTEMI) from unstable angina (see the image below.)

Time course of elevations of serum markers after a Time course of elevations of serum markers after acute myocardial infarction. CK = creatine kinase; CK-MB = creatine kinase MB fraction; LDH = lactate dehydrogenase.

In addition, biomarkers alone or as part of accelerated diagnostic protocols (ADP) may reduce the number of patients with a missed diagnosis of NSTEMI who are at increased risk for major adverse cardiac events.

Furthermore, such approaches may facilitate early discharge from the ED in patients who have a low short-term risk of a major cardiac event, as reported by the ASPECT (ASia-Pacific Evaluation of Chest pain Trial) investigators.[26] However, the trial did not fully address the potentially important influence of cultural differences in chest pain perception and time to presentation.

The current standard of care includes drawing blood for total CK-MB levels every 6-8 hours during the first 24 hours. In addition, it is important to determine cardiac-specific troponin (T or I) levels at least twice, 6-8 hours apart, because these markers may initially be negative, especially within 2-4 hours of chest pain. If patients have persistent or recurrent symptoms or if the index of suspicion is high, additional measurements of CK-MB, or troponin if initially negative, should be considered.

Troponin I levels of 0.4 ng/mL or higher or troponin T levels of 0.1 ng/mL or higher are considered positive and have been associated with higher short-term and midterm mortality. Outcomes in troponin-positive patients have been improved by aggressive treatment strategies that include early cardiac catheterization. The temporal trends of these assays are helpful in interpreting difficult cases, and mild elevations of CK-MB or troponins from a lower baseline with subsequent falls in levels strongly indicate the occurrence of myonecrosis.

Troponin levels also may still capture evidence of a cardiac event in patients who delay their presentation to the hospital, because the serum half-life of troponin is longer than that of CK-MB and can remain elevated for 7-14 days after an event. Because of their kinetics, however, cardiac troponins, once elevated, are much less useful in evaluating recurrent chest pain with myocardial injury, whereas CK-MB levels permit detection of reinfarction.

Because measurement of troponin is a very sensitive assay that detects myocardial injury or necrosis in the absence of CAD (eg, in critically ill or septic patients), newer mechanistic criteria have been put forth for a universal definition of MI by a joint task force of the European Society of Cardiology (ESC), the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the World Heart Federation (WHF).[27]

Fundamentally, this universal definition tries to identify patients in whom there may be an ACS wherein investigation or intervention might improve outcome (type I, or “spontaneous MI”).[27] Such an individual is distinguished from the patient in an intensive care unit (ICU) who has a type 2 MI or troponin elevation that is related to myocardial necrosis due to a supply-demand mismatch (eg, anemia, tachycardia, respiratory failure, or hypotension due to sepsis).

Although elevated troponins portend a graver prognosis for all of these cohorts, the latter patients are unlikely to benefit from an ischemia workup—and may indeed be harmed by an invasive strategy.[27]

There are also data suggesting that troponin T may be falsely elevated with major injury to skeletal muscles. Furthermore, qualitative bedside troponin assay results may be difficult to interpret in patients with renal insufficiency.

Brain natriuretic peptide

The TACTICS/TIMI (Treat angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy/Thrombolysis In Myocardial Infarction)-18 substudy showed that brain (B-type) natriuretic peptide (BNP) is an independent predictor of short- and long-term mortality and risk of CHF in patients presenting with unstable angina.[28]

Elevated BNP levels have also been linked to more significant coronary artery lesions in patients with unstable angina, including patients with greater left anterior descending (LAD) artery involvement.

BNP levels may add incremental information to the assessment of patients with unstable angina, but they should be used in context with other cardiac markers to guide medical decision making. The cost-effectiveness of routine use of multiple cardiac biomarkers has not been established.

Combination with C-reactive protein

In the future, a combination of levels of troponin (a biomarker of myocardial necrosis), N-terminal pro-B-type natriuretic peptide (NT-proBNP) (an indicator of elevated left ventricular end-diastolic pressure and wall stress), and C-reactive protein (CRP) (an estimate of extent of systemic inflammation) may prove useful for predicting the outcome of patients with ACS.

Previous
Next

Electrocardiography

The first line of assessment in any patient with suspected unstable angina is the 12-lead ECG, which should be obtained within 10 minutes of the patient’s arrival in the ED. The diagnostic accuracy of an ECG is enhanced if a prior tracing is available for comparison. Serial ECG recordings taken every 15-30 minutes are recommended if the patient’s chest pain continues and ECG changes are not noted in the initial or subsequent recordings.[29]

The highest-risk ECG findings (ST-segment elevation or new left bundle branch block) necessitate immediate triage for revascularization therapy. Peaked T waves may also indicate early MI.

The next level of high-risk patients includes those with ST depression greater than 1 mm on ECG. Approximately 50% of patients with this finding have subendocardial myocardial necrosis. The presence of ST-segment depression portends relatively high in-hospital, 30-day, and 1-year mortalities, irrespective of cardiac biomarker level.

New or reversible ST-segment deviation of 0.5 mm or more from baseline was associated with a higher incidence (15.8% vs 8.2%) of 1-year death or MI in the TIMI-III Registry ECG Ancillary study.[17]

Primary T wave changes are neither sensitive nor specific for ischemia, but they become an important clue in the context of the patient’s symptoms or if the QRS to T-wave angle is greater than 60°. Isolated symmetric T-wave inversion does not appear to carry additional adverse prognosis.

Wellens syndrome

Wellens syndrome refers to specific ECG abnormalities in the precordial T-wave segment, which are associated with critical stenosis of the proximal LAD coronary artery. De Zwaan, Wellens, and colleagues in the early 1980s recognized this subset of patients with unstable angina who had specific precordial T-wave inversions and subsequently developed a large anterior wall MY.[30] Wellens syndrome is also referred to as LAD coronary T-wave syndrome.[31] Syndrome criteria include the following:

  • Characteristic T-wave changes
  • A history of anginal chest pain
  • Normal or minimally elevated cardiac enzyme levels
  • An ECG without Q waves, without significant ST elevation, and with normal precordial R-wave progression

Recognition of this ECG abnormality is of paramount importance because LAD coronary T-wave syndrome represents a preinfarction stage of CAD that often progresses to a devastating anterior wall infarction.

Previous
Next

Echocardiography

If available on a prompt basis, echocardiography can provide a quick evaluation of left ventricular function either for prognosis (which is worse when the left ventricular ejection fraction [LVEF] is less than 40%) or for diagnosis, as when new segmental wall motion abnormality is detected (eg, in postinfarction or postrevascularization chest pain in which baseline left ventricular function is known). However, it must be kept in mind that small infarcts may not be apparent on the echocardiogram.

Important causes of chest pain, such as aortic stenosis and hypertrophic obstructive cardiomyopathy (HOCM), can be readily detected by echocardiography.

Transesophageal echocardiography is highly recommended if the clinical picture suggests the possibility of a valvular or mechanical complication of MI or if the patient is not following the expected hospital course.

Transesophageal echocardiography, computed tomography angiography (CTA), or magnetic resonance angiography (MRA) is invaluable when aortic dissection is being ruled out.

Previous
Next

SPECT and MRI

The sensitivity of single-photon emission computed tomography (SPECT) is sufficient to detect infarcts of at least 10 g, but magnetic resonance imaging (MRI) with gadolinium enhancement may depict infarcts as small as 1-5 g.

MRI has emerging applications for identifying ischemia (space-time maps of impaired blood arrival), infarction (wall thinning, scar, or delayed enhancement), and wall-motion abnormalities that may be coupled with coronary artery MRA in the future.

MRI is well established as a means of detecting myocardial scarring of as little as 1%, which is a powerful prognostic factor.[32, 33] It is also well established for detecting and characterizing complications of MI. MRI may find wall-motion abnormalities and infarcts missed by echocardiography, whether because of the higher resolution and full coverage of MRI, because of echocardiography dropout from the lungs or ribs, or because of the angle dependence of echocardiography, which may miss the affected area, such as the real apex.

Previous
Next

Myocardial Perfusion Imaging

Myocardial perfusion imaging is a valuable method for triaging patients with chest pain in the ED. Myocardial perfusion imaging at rest is highly sensitive for detecting acute MI, and it can be supplemented with provocative testing after infarction is excluded. However, the results of clinical trials can be applied only in centers with proven reliability and experience.

Previous
Next

Exercise Testing

Exercise testing is not typically performed in the acute phase of unstable angina or in subjects with recent rest angina. However, subjects in whom disease activity becomes controlled after several days of medical therapy may safely undergo stress testing before hospital discharge.

When feasible, predischarge testing is preferential to testing weeks to months after discharge because no prognostic value is lost with early testing and because a relatively high proportion of adverse cardiac events occur earlier rather than later.

Predischarge exercise tests add independent prognostic information to known important clinical descriptors, such as recurrent rest pain and evolutionary T-wave changes. For example, patients who had a reversible defect on nuclear stress testing had a 25% incidence of death or MI at 1 year, compared with an incidence of only 2% for those with a negative scan.[34] Among men, shorter exercise duration, lower maximal rate-pressure product, and exercise-induced angina or ST-segment depression have correlated with unfavorable outcome.[35]

Although the negative predictive value is on the order of 90% across the board for all modalities of stress tests, the positive predictive value is poor (16-19%) for exercise or adenosine stress tests and only moderately better (31-48%) for the imaging stress tests.

Many chest pain centers are evaluating early stress testing for expeditious triage of low-risk patients. The ERASE Chest Pain (Emergency Room Assessment of Sestamibi for Evaluation of Chest Pain) randomized clinical trial compared usual care with usual care plus a resting perfusion scan in patients with and ECG that was normal or nondiagnostic for ischemia.[35] There was a 32% reduction in the odds of being unnecessarily admitted to the hospital, without sacrifice of safety, in nonischemic patients who underwent early nuclear perfusion scanning.

No large studies comparing the performance characteristics of the different stress-testing modalities in the specific setting of unstable angina are available.

Previous
 
 
Contributor Information and Disclosures
Author

Walter Tan, MD, MS Associate Professor of Medicine, Wake Forest University School of Medicine; Director of Cardiac Cath Labs, Wake Forest Baptist Medical Center

Walter Tan, MD, MS is a member of the following medical societies: American Association for the Advancement of Science, American College of Cardiology, American Heart Association, American Stroke Association, National Stroke Association, Society for Vascular Medicine, Society of Interventional Radiology

Disclosure: Nothing to disclose.

Coauthor(s)

David J Moliterno, MD Professor of Medicine, Jefferson Morris Gill Professor of Cardiology, Chief, Division of Cardiovascular Medicine, University of Kentucky; Vice Chairman of Internal Medicine, Chandler Medical Center; Medical Director, Gill Heart Institute

David J Moliterno, MD is a member of the following medical societies: American College of Cardiology, European Society of Cardiology, Association of Professors of Cardiology, American College of Physicians, American Heart Association, American Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Chief Editor

Eric H Yang, MD Associate Professor of Medicine, Director of Cardiac Catherization Laboratory and Interventional Cardiology, Mayo Clinic Arizona

Eric H Yang, MD is a member of the following medical societies: Alpha Omega Alpha

Disclosure: Nothing to disclose.

Acknowledgements

Steven James Filby, MD Fellow in Interventional Cardiology, The Cleveland Clinic Foundation

Disclosure: Nothing to disclose.

Justin D Pearlman, MD, ME, PhD, FACC, MA Chief, Division of Cardiology, Director of Cardiology Consultative Service, Director of Cardiology Clinic Service, Director of Cardiology Non-Invasive Laboratory, Director of Cardiology Quality Program KMC, Dartmouth-Hitchcock Medical Center, Dartmouth Medical School

Justin D Pearlman, MD, ME, PhD, FACC, MA is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Federation for Medical Research, International Society for Magnetic Resonance in Medicine, and Radiological Society of North America

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. Basra SS, Virani SS, Paniagua D, Kar B, Jneid H. Acute coronary syndromes: unstable angina and non-ST elevation myocardial infarction. Heart Fail Clin. 2016 Jan. 12 (1):31-48. [Medline].

  2. What are the symptoms of heart attack and unstable angina?. eMedicineHealth. May 8, 2013. Available at http://www.emedicinehealth.com/heart_attack_and_unstable_angina-health/page5_em.htm#Symptoms.. Accessed: May 9, 2013.

  3. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011 Jan 20. 364(3):226-35. [Medline].

  4. Harrap SB, Zammit KS, Wong ZY, et al. Genome-wide linkage analysis of the acute coronary syndrome suggests a locus on chromosome 2. Arterioscler Thromb Vasc Biol. 2002 May 1. 22(5):874-8. [Medline].

  5. Zhao YH, Xu Y, Gu YY, Li Y, Zhang JY, Su X. Functional effect of platelet membrane glycoprotein ia gene polymorphism in the pathogenesis of unstable angina pectoris. J Int Med Res. 2011. 39(2):541-8. [Medline].

  6. Fiotti N, Moretti ME, Bussani R, et al. Features of vulnerable plaques and clinical outcome of UA/NSTEMI: Relationship with matrix metalloproteinase functional polymorphisms. Atherosclerosis. 2011 Mar. 215(1):153-9. [Medline].

  7. White AJ, Duffy SJ, Walton AS, et al. Matrix metalloproteinase-3 and coronary remodelling: implications for unstable coronary disease. Cardiovasc Res. 2007 Sep 1. 75(4):813-20. [Medline].

  8. Manzoli A, Andreotti F, Varlotta C, et al. Allelic polymorphism of the interleukin-1 receptor antagonist gene in patients with acute or stable presentation of ischemic heart disease. Cardiologia. 1999 Sep. 44(9):825-30. [Medline].

  9. Tziakas DN, Chalikias GK, Antonoglou CO, et al. Apolipoprotein E genotype and circulating interleukin-10 levels in patients with stable and unstable coronary artery disease. J Am Coll Cardiol. 2006 Dec 19. 48(12):2471-81. [Medline].

  10. Willerson JT. Systemic and local inflammation in patients with unstable atherosclerotic plaques. Prog Cardiovasc Dis. 2002 May-Jun. 44(6):469-78. [Medline].

  11. Scirica BM, Moliterno DJ, Every NR, et al. Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry). The GUARANTEE Investigators. Am J Cardiol. 1999 Nov 15. 84(10):1145-50. [Medline].

  12. Skolnick AH, Alexander KP, Chen AY, et al. Characteristics, management, and outcomes of 5,557 patients age > or =90 years with acute coronary syndromes: results from the CRUSADE Initiative. J Am Coll Cardiol. 2007 May 1. 49(17):1790-7. [Medline].

  13. Hoekstra JW, Pollack CV Jr, Roe MT, et al. Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. Acad Emerg Med. 2002 Nov. 9(11):1146-55. [Medline].

  14. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Lancet. 1999 Feb 6. 353(9151):429-38. [Medline].

  15. Luepker RV. WHO MONICA project: what have we learned and where to go from here?. Public Health Rev. 2012. Accessed: May 8, 2013. 33(2):373-96. [Full Text].

  16. GRACE, Global Registry of Acute Coronary Events. Available at http://www.outcomes-umassmed.org/grace/. Accessed: September 16, 2010.

  17. Cannon CP, McCabe CH, Stone PH, et al. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia. J Am Coll Cardiol. 1997 Jul. 30(1):133-40. [Medline].

  18. Lupon J, Valle V, Marrugat J, et al. Six-month outcome in unstable angina patients without previous myocardial infarction according to the use of tertiary cardiologic resources. RESCATE Investigators. Recursos Empleados en el Síndrome Coronario Agudo y Tiempos de Espera. J Am Coll Cardiol. 1999 Dec. 34(7):1947-53. [Medline].

  19. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10. 361(11):1045-57. [Medline].

  20. Tanindi A, Erkan AF, Ekici B. Epicardial adipose tissue thickness can be used to predict major adverse cardiac events. Coron Artery Dis. 2015 Dec. 26 (8):686-91. [Medline].

  21. Karcz A, Holbrook J, Burke MC, et al. Massachusetts emergency medicine closed malpractice claims: 1988-1990. Ann Emerg Med. 1993 Mar. 22(3):553-9. [Medline].

  22. Li Z, Liu X, Wang J, et al. Analysis of urinary metabolomic profiling for unstable angina pectoris disease based on nuclear magnetic resonance spectroscopy. Mol Biosyst. 2015 Dec 10. 11 (12):3387-96. [Medline].

  23. Gurses KM, Kocyigit D, Yalcin MU, et al. Enhanced platelet toll-like receptor 2 and 4 expression in acute coronary syndrome and stable angina pectoris. Am J Cardiol. 2015 Dec 1. 116 (11):1666-71. [Medline].

  24. Meune C, Balmelli C, Twerenbold R, et al. Patients with acute coronary syndrome and normal high-sensitivity troponin. Am J Med. 2011 Dec. 124(12):1151-7. [Medline].

  25. Misra D, Leibowitz K, Gowda RM, Shapiro M, Khan IA. Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis. Clin Cardiol. 2004 Nov. 27(11):607-10. [Medline].

  26. Than M, Cullen L, Reid CM, et al. A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study. Lancet. 2011 Mar 26. 377(9771):1077-84. [Medline].

  27. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012 Oct. 33(20):2551-67. [Medline]. [Full Text].

  28. Januzzi JL, Cannon CP, DiBattiste PM, Murphy S, Weintraub W, Braunwald E. Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). Am J Cardiol. 2002 Dec 1. 90(11):1246-9. [Medline].

  29. [Guideline] Acute coronary syndrome and myocardial infarction. EBM Guidelines. Evidence-Based Medicine [internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons; 2011. [Full Text].

  30. de Zwaan C, Bar FW, Wellens HJ. Characteristic electrocardiographic pattern indicating a critical stenosis high in left anterior descending coronary artery in patients admitted because of impending myocardial infarction. Am Heart J. Apr 1982. ;103(4 Pt 2):730-6. [Medline].

  31. Nisbet BC, Zlupko G. Repeat Wellens' syndrome: case report of critical proximal left anterior descending artery restenosis. J Emerg Med. 2010 Sep. 39(3):305-8. [Medline].

  32. Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation. 2006 Jun 13. 113(23):2733-43. [Medline].

  33. Kwong RY, Sattar H, Wu H, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation. 2008 Sep 2. 118(10):1011-20. [Medline]. [Full Text].

  34. Stratmann HG, Younis LT, Wittry MD, Amato M, Miller DD. Exercise technetium-99m myocardial tomography for the risk stratification of men with medically treated unstable angina pectoris. Am J Cardiol. 1995 Aug 1. 76(4):236-40. [Medline].

  35. Udelson JE, Spiegler EJ. Emergency department perfusion imaging for suspected coronary artery disease: the ERASE Chest Pain Trial. Md Med. 2001 Spring. Suppl:90-4. [Medline].

  36. [Guideline] Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Jun 11. 61(23):e179-347. [Medline].

  37. Busko M. New non-ST-elevation ACS guidelines: new title, new approach. Medscape Medical News from WebMD. September 29, 2014. Available at http://www.medscape.com/viewarticle/832513. Accessed: October 4, 2014.

  38. [Guideline] Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23. 64(24):e139-228. [Medline].

  39. [Guideline] Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interv... Circulation. 2007 Aug 14. 116(7):e148-304. [Medline].

  40. [Guideline] Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011 May 10. 123(18):2022-60. [Medline].

  41. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 Aug 16. 345(7):494-502. [Medline].

  42. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003 Oct 7. 108(14):1682-7. [Medline].

  43. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 Nov 20. 288(19):2411-20. [Medline].

  44. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009 Jan 22. 360(4):354-62. [Medline].

  45. Pare G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010 Oct 28. 363(18):1704-14. [Medline].

  46. Park KW, Kim HS. Options to overcome clopidogrel response variability. Circ J. 2012. 76(2):287-92. [Medline].

  47. O'Connor FF, Shields DC, Fitzgerald A, Cannon CP, Braunwald E, Fitzgerald DJ. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood. 2001 Dec 1. 98(12):3256-60. [Medline].

  48. De Servi S, Goedicke J, Schirmer A, Widimsky P. Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. Eur Heart J Acute Cardiovasc Care. 2014 Dec. 3(4):363-72. [Medline].

  49. National Clinical Guideline Centre for Acute and Chronic Conditions. Unstable angina and NSTEMI: the early management of unstable angina and non-ST-segment-elevation myocardial infarction. London, UK: National Institute for Health and Clinical Excellence; 2010. [Full Text].

  50. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012 Aug 14. 60(7):645-81. [Medline].

  51. US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack [press release]. AstraZeneca. September 3, 2015. Available at http://www.astrazeneca.com/Media/Press-releases/Article/20150903. Accessed: September 9, 2015.

  52. Bonaca MP, Bhatt DL, Cohen M, et al, for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015 May 7. 372 (19):1791-800. [Medline].

  53. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001 Jun 16. 357(9272):1915-24. [Medline].

  54. Ibbotson T, McGavin JK, Goa KL. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs. 2003. 63(11):1121-63. [Medline].

  55. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation. 2001 Dec 4. 104(23):2767-71. [Medline].

  56. Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N, Magee K. Heparin versus placebo for non-ST elevation acute coronary syndromes. Cochrane Database Syst Rev. 2014 Jun 27. 6:CD003462. [Medline].

  57. Cohen M, Demers C, Gurfinkel EP, et al. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and safety of subcutaneous enoxaparin versus intravenous unfractionated heparin, in non-Q-wave coronary events. Am J Cardiol. 1998 Sep 10. 82(5B):19L-24L. [Medline].

  58. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004 Jul 7. 292(1):45-54. [Medline].

  59. Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol. 2007 Oct 30. 50(18):1742-51. [Medline].

  60. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 1992 Jul 16. 327(3):141-5. [Medline].

  61. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet. 2002 Jan 26. 359(9303):294-302. [Medline].

  62. Metz BK, White HD, Granger CB, et al. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. J Am Coll Cardiol. 1998 Jun. 31(7):1493-8. [Medline].

  63. Maroo A, Lincoff AM. Bivalirudin in PCI: an overview of the REPLACE-2 trial. Semin Thromb Hemost. 2004 Jun. 30(3):329-36. [Medline].

  64. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006 Nov 23. 355(21):2203-16. [Medline].

  65. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001 Apr 4. 285(13):1711-8. [Medline].

  66. Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009 Dec 15. 54(25):2358-62. [Medline].

  67. US FDA. Safety: statin drugs - drug safety communication: class labeling change. US Food and Drug Administration. February 28, 2012. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm293670.htm. Accessed: June 5, 2013.

  68. US FDA. Safety: Zocor (simvastatin): label change - new restrictions, contraindications, and dose limitations. US Food and Drug Administration. June 8, 2011. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm258384.htm. Accessed: June 5, 2013.

  69. US FDA. Safety: Meridia (sibutramine): market withdrawal due to risk of serious cardiovascular events. US Food and Drug Administration. October 8, 2010. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm228830.htm. Accessed: June 5, 2013.

  70. Soukoulis V, Boden WE, Smith SC Jr, O'Gara PT. Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon. Circ Res. 2014 Jun 6. 114(12):1944-58. [Medline]. [Full Text].

  71. Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol. 1995 Dec. 26(7):1643-50. [Medline].

  72. Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med. 1998 Jun 18. 338(25):1785-92. [Medline].

  73. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet. 1999 Aug 28. 354(9180):708-15. [Medline].

  74. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet. 2002 Sep 7. 360(9335):743-51. [Medline].

  75. Damman P, Hirsch A, Windhausen F, Tijssen JG, de Winter RJ. 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2010 Mar 2. 55(9):858-64. [Medline].

  76. Neumann FJ, Kastrati A, Pogatsa-Murray G, et al. Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA. 2003 Sep 24. 290(12):1593-9. [Medline].

  77. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stale E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet. 2000 Jul 1. 356(9223):9-16. [Medline].

  78. [Guideline] American Diabetes Association. Standards of medical care in diabetes--2010. Diabetes Care. 2010 Jan. 33 Suppl 1:S11-61. [Medline]. [Full Text].

 
Previous
Next
 
Pathogenesis of acute coronary syndromes.
Thrombolysis in Myocardial Infarction (TIMI) Risk Score correlates with major adverse outcome and effect of therapy with low-molecular-weight heparin. ARD = absolute risk difference; ESSENCE = Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q-wave Coronary Events; No. = number; NNT = number needed to treat.
Algorithm for initial invasive strategy. ASA = acetylsalicylic acid (aspirin); GP IIb/IIIa= glycoprotein IIb/IIIa; IV = intravenous; LOE = level of evidence; UA/NSTEMI = unstable angina/non–ST-segment elevation myocardial infarction; UFH = unfractionated heparin. (Adapted from 2007 ACC/AHA UA/NSTEMI Guidelines.)
Algorithm for initial conservative strategy. ASA = acetylsalicylic acid (aspirin); EF = ejection fraction; GP IIb/IIIa= glycoprotein IIb/IIIa; IV = intravenous; LOE = level of evidence; LVEF = left ventricular ejection fraction; UA/NSTEMI = unstable angina/non–ST-segment elevation myocardial infarction. (Adapted from 2007 ACC/AHA UA/NSTEMI Guidelines.)
Rate and timing of revascularization for patients with unstable angina using invasive versus conservative approach (FRagmin during InStability in Coronary artery disease [FRISC] II).
Time course of elevations of serum markers after acute myocardial infarction. CK = creatine kinase; CK-MB = creatine kinase MB fraction; LDH = lactate dehydrogenase.
Table 1. Patient Characteristics, GUARANTEE Versus CRUSADE Trials
Characteristics GUARANTEE, 1995-96 [11] CRUSADE, 2001-06 [12]
Mean age (y) 62 69
Patients >65 y (%) 44
Female (%) 39 40
Hypertension (%) 60 73
Diabetes mellitus (%) 26 33
Current smoker (%) 25
Hypercholesterolemia (%) 43 50
Previous stroke (%) 9
Previous MI (%) 36 30
Previous angina (%) 66
CHF (%) 14 18
Previous coronary intervention (%) 23 21
Previous coronary bypass surgery (%) 25 19
CHF = congestive heart failure; CRUSADE = Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines; GUARANTEE = Global Unstable Angina Registry and Treatment Evaluation; MI = myocardial infarction.
Table 2. Demographic Characteristics of Patients in International OASIS-2 Registry
Characteristics [14] Australia Brazil Canada Hungary Poland United States
General Number of patients 1899 1478 1626 931 1135 918
Mean age (y) 65 62 66 65 63 66
Women (%) 37 42 37 45 40 37
Clinical NQMI presentation (%) 7 7 14 22 17 16
Abnormal ECG (%) 74 91 82 95 97 87
Select treatments Beta blocker (%) 67 53 73 67 59 57
Calcium blocker (%) 59 51 53 52 43 59
Invasive procedures (index hospitalization) Cardiac catheterization (%) 24 69 43 20 7 58
PCI (%) 7 19 16 5 0.4 24
CABG (%) 4 20 10 7 0.4 17
CABG = coronary artery bypass grafting; ECG = electrocardiographic; NQMI = non-Q wave myocardial infarction; OASIS = Organization to Assess Strategies for Ischemic Syndromes; PCI = percutaneous coronary intervention.
Table 3. Thirty-Day Clinical Outcome in Patients With Acute Coronary Syndromes in Clinical Trials
Study Year Number of Patients Death (%) Myocardial Infarction (%) Major Bleed (%)
TIMI-3 1994 1,473 2.5 9.0 0.3
GUSTO-IIb 1997 8,011 3.8 6.0 1.0
ESSENCE 1998 3,171 3.3 4.5 1.1
PARAGON-A 1998 2,282 3.2 10.3 4.0
PRISM 1998 3,232 3.0 4.2 0.4
PRISM-PLUS 1998 1,915 4.4 8.1 1.1
PURSUIT 1998 10,948 3.6 12.9 2.1
TIMI-11B 1999 3,910 3.9 6.0 1.3
PARAGON-B 2000 5,225 3.1 9.3 1.1
Pooled 40,167 3.5 8.5 1.5
ESSENCE = Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q-wave Coronary Events; GUSTO-IIb = Global Utilization of Streptokinase and TPA (tissue plasminogen activator) for Occluded Coronary Arteries; PARAGON-A = Platelet IIb/IIIa Antagonism (lamifiban) for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network; PARAGON-B = Platelet IIb/IIIa Antagonism (lamifiban) for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network; PRISM = Platelet Receptor Inhibition in Ischemic Syndrome Management; PRISM-PLUS = Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Angina Signs and Symptoms; PURSUIT = Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy; TIMI-11B = Thrombolysis in Myocardial Infarction Clinical Trial 11B; TIMI-3 = Thrombolysis in Myocardial Infarction Clinical Trial 3.
Table 4. Braunwald Classification of Unstable Angina
Characteristic Class/Category Details
Severity I Symptoms with exertion
II Subacute symptoms at rest (2-30 days prior)
III Acute symptoms at rest (within prior 48 hr)
Clinical precipitating factor A Secondary
B Primary
C Postinfarction
Therapy during symptoms 1 No treatment
2 Usual angina therapy
3 Maximal therapy
Table 5. ACC/AHA Recommendations for Preferred Invasive Strategy
Preferred Strategy [39] Patient Characteristics
Invasive Recurrent angina/ischemia at rest or with low-level activities despite intensive medical therapy
Elevated cardiac biomarkers (TnT or TnI)
New or presumably new ST-segment depression
Signs or symptoms of heart failure or new or worsening mitral regurgitation
High-risk findings on noninvasive stress testing
High-risk score (eg, TIMI, GRACE)
Reduced LV systolic function (LVEF < 40%)
Hemodynamic instability
Sustained ventricular tachycardia
PCI within 6 months
Previous CABG
Conservative Low-risk score (eg, TIMI, GRACE)
Patient or physician preference in the absence of high-risk features
ACC/AHA = American College of Cardiology/American Heart Association; CABG = coronary artery bypass grafting; GRACE = Global Registry of Acute Coronary Events; LV = left ventricle; LVEF = left ventricular ejection fraction; PCI = percutaneous coronary intervention; TIMI = Thrombolysis in Myocardial Infarction Clinical Trial; TnI = troponin I; TnT = troponin T.
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.